Skip to main content
Clinical Trials/ISRCTN20781131
ISRCTN20781131
Completed
未知

High-risk human papillomavirus (HrHPV) in the population research on cervical cancer: a randomised clinical trial

Vrije University Medical Centre (VUMC) (The Netherlands)0 sites44,102 target enrollmentDecember 20, 2005

Overview

Phase
未知
Intervention
Not specified
Conditions
Cervical intraepithelial neoplasia
Sponsor
Vrije University Medical Centre (VUMC) (The Netherlands)
Enrollment
44102
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

2004 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/15054873 Design, methods and baseline data: 2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15900579 Association between higher-grade CIN and HPV type 2007 Other publications in http://www.ncbi.nlm.nih.gov/pubmed/17919718 5-year follow-up 2012 Results article in http://www.ncbi.nlm.nih.gov/pubmed/22177579 Final results 2018 Other publications in https://www.ncbi.nlm.nih.gov/pubmed/29663363 Post hoc analysis of 14-year follow-up data 2022 Other publications in https://pubmed.ncbi.nlm.nih.gov/36306283/ Association between cervical precancer risk at 14 years and previous screening results (added 31/10/2022)

Registry
who.int
Start Date
December 20, 2005
End Date
September 1, 2007
Last Updated
3 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Vrije University Medical Centre (VUMC) (The Netherlands)

Eligibility Criteria

Inclusion Criteria

  • 1\. Women invited for the cervical cancer screening program (ages 30 \- 60 years)
  • 2\. Residing in either the region covered by district health authority Amstelland\-de Meerlanden and Zuid\-Kennemerland

Exclusion Criteria

  • 1\. Not called for screening, ie ages under 30 years, or over 60 years
  • 2\. Follow\-up of previous non\-normal cytology within the current screening round of the program, i.e., abnormal cytology or CIN lesions less than two years before inclusion
  • 3\. Status after extirpation of the uterus or amputation of the portio

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Epidemiological analysis of human papillomavirus in western Kazakhstan in relation to HPV-attributable cervical pathology – social, clinical and genetic aspectsCervical cancerCancerMalignant neoplasm of cervix uteri
ISRCTN71514910Committee of Science of the Ministry of Education and Science of the Republic of Kazakhstan1,166
Completed
Not Applicable
HrHPV in the population research on cervical cancer.Cervical intraepithelial neoplasia and cervical cancer. Due to the low prevalence of invasive cervical cancer in the Netherlands, and the aim of cervical screening to prevent the occurrence of and death caused by to cervical cancer, we evaluate the prevalence of a surrogate marker for cervical cancer incidence, namely the immediate precursor lesion of cervical cancer cervical intra-epithelial neoplasia grade 3.
NL-OMON28695- Department of Pathology, VU University Medical Center- Department of Pathology, Spaarne Ziekenhuis, Hoofddorp- Leiden Cytology and Pathology Laboratory, Leiden- Stichting PA Laboratorium Kennemerland, Haarlem44,102
Completed
Not Applicable
Human papillomavirus (HPV) vaccine in human immunodeficiency virus (HIV) positive girls and womeHuman immunodeficiency virus, human papillomavirusInfections and InfestationsHuman immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseases
ISRCTN33674451Women's Health Research Institute (WHRI) (Canada)500
Completed
Not Applicable
Epidemiological studies on human papillomavirus (HPV)
ISRCTN90378590ondon School of Hygiene & Tropical Medicine (UK)330
Completed
Phase 2
Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod TreatmentHPV
NCT00941811Medical University of Vienna5